Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Editas Medicine Inc EDIT

Healthcare Biotechnology
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9... see more

Recent & Breaking News (NDAQ:EDIT)

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire October 13, 2022

Editas Medicine to Participate in Upcoming Investor Conferences

GlobeNewswire September 1, 2022

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

GlobeNewswire August 3, 2022

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

GlobeNewswire July 27, 2022

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

GlobeNewswire July 26, 2022

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

GlobeNewswire July 20, 2022

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire July 18, 2022

Immatics and Editas Medicine Enter Strategic Research Collaboration and Licensing Agreement to Combine Gamma-Delta T Cell Adoptive Cell Therapies and Gene Editing for the Treatment of Cancer

GlobeNewswire June 7, 2022

Editas Medicine Reports Inducement Grants to New Chief Executive Officer

GlobeNewswire June 6, 2022

Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 18, 2022

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta Thalassemia

GlobeNewswire May 12, 2022

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

GlobeNewswire May 4, 2022

Editas Medicine Announces First Quarter 2022 Results and Business Updates

GlobeNewswire May 4, 2022

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire May 2, 2022

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

GlobeNewswire April 27, 2022

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

GlobeNewswire April 26, 2022

Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

GlobeNewswire April 14, 2022

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

GlobeNewswire April 11, 2022

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

GlobeNewswire April 8, 2022

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

GlobeNewswire February 28, 2022